Radioimmunotherapy of non-Hodgkin's lymphoma [6]

Journal of Nuclear Medicine

Volumn 45, Issue 5, 2004, Pages 924-925

  Britton, Keith E ^a  

^a ST BARTHOLOMEW S HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

(3 IODOBENZYL)GUANIDINE I 131; IBRITUMOMAB TIUXETAN; IODINE 123; PENTETREOTIDE IN 111; TOSITUMOMAB I 131; UNCLASSIFIED DRUG; Y90 OCTREOTHER; MONOCLONAL ANTIBODY; RADIOACTIVE IODINE; YTTRIUM;

DOSIMETRY; DRUG UPTAKE; HUMAN; LETTER; NONHODGKIN LYMPHOMA; OUTCOME ASSESSMENT; PRIORITY JOURNAL; RADIATION DOSE; RADIOIMMUNOTHERAPY; THYROID CANCER; TUMOR VOLUME; NOTE;

ANTIBODIES, MONOCLONAL; HUMANS; IODINE RADIOISOTOPES; LYMPHOMA, NON-HODGKIN; RADIOIMMUNOTHERAPY; YTTRIUM RADIOISOTOPES;

EID: 2642516526     PISSN: 01615505     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Letter

References (8)

1. 131I-tositumomab therapy of previously untreated lymphoma patients. J Nucl Med. 2003;44:457-464.
2. 90Y-ibritumomab tiuxetan radioimmunotherapy for relapsed or refractory non-Hodgkin's lymphoma: combined data from 4 clinical trials. J Nucl Med. 2003;44:465-474.
3. 90Y-Zevalin (yttrium-90 ibritumomab tiuxetan, IDEC-Y2B8) radioimmunotherapy dosimetry results in relapsed or refractory non-Hodgkin's lymphoma. Eur J Nucl Med. 2000;27:766-777.
4. 90Y-labelled anti-CD20 monoclonal antibody. J Nucl Med. 2002;43:267-272.
5. Britton KE, Granowska M. Cancer: find and treat the individual, the nuclear medicine approach. World J Nucl Med. 2002;1:75-79.
6. 131I-scanning: avoidance of negative therapeutic uptake due to stunning. Clin Endocrinol. 2001;55:515-521.
7. Britton KE, Foley RR, Chew SL. Should hTg levels in the absence of iodine uptake be treated? Eur J Nucl Med Mol Imaging. 2003;30:794-795.
8. Dorn R, Kopp J, Vogt H, Heidenreich P, Carroll RG, Gulec SA. Dosimetry-guided radioactive iodine treatment in patients with metastatic differentiated thyroid cancer: largest safe dose using a risk-adapted approach. J Nucl Med. 2003;44:451-456.